Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Avantor, Inc.AVTR · Entity 3546 | EVP, Biopharma Production | May 17, 2023 | May 19, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Avantor, Inc.
Report date May 17, 2023 · Filed May 19, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 89,032 |
Reported balance
After 2023-05-17 transaction · row 1
1 source rowRow 1 · 2023-05-17 · Tax withholding · Disposed 19,683 · Balance 89,032 F1: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 17, 2023 Filed May 19, 2023 20:19 UTC | Avantor, Inc. AVTR · Entity 3546 | Tax withholdingCommon Stock | 19,683 | $20.28 | $399,171.24 |
DisclosureSEC source: 0001722482-23-000134 · wf-form4_168452755791801.xml · nonDerivative · entry 1 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,032 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| March 03, 2023 Filed Mar 6, 2023 21:38 UTC | Avantor, Inc. AVTR · Entity 3546 | SaleCommon Stock | 3,914 | $25.00 | $97,850.00 |
DisclosureSEC source: 0001722482-23-000081 · wf-form4_167813867634083.xml · nonDerivative · entry 1 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,715 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 21:46 UTC | Avantor, Inc. AVTR · Entity 3546 | SaleCommon Stock | 3,059 | $25.00 | $76,475.00 |
DisclosureSEC source: 0001722482-23-000079 · wf-form4_167770717509179.xml · nonDerivative · entry 1 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,629 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| February 25, 2023 Filed Feb 28, 2023 01:10 UTC | Avantor, Inc. AVTR · Entity 3546 | Tax withholdingCommon Stock | 2,040 | $24.62 | $50,224.80 |
DisclosureSEC source: 0001722482-23-000075 · wf-form4_167754659342287.xml · nonDerivative · entry 3 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,688 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 01:10 UTC | Avantor, Inc. AVTR · Entity 3546 | GrantStock Options (Right to Buy) · Derivative | 49,215 | $0.00 Strike: $24.62 | $0.00 |
DisclosureSEC source: 0001722482-23-000075 · wf-form4_167754659342287.xml · derivative · entry 4 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,215 Underlying: Common Stock · 49,215 shares Expires 2033-02-24 F3 · derivative.exercise_date: Reflects a grant of stock options that vest in four equal annual installments beginning on February 24, 2024. Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 01:10 UTC | Avantor, Inc. AVTR · Entity 3546 | GrantCommon Stock | 20,308 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-23-000075 · wf-form4_167754659342287.xml · nonDerivative · entry 2 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,728 F2 · kind: Reflects a grant of restricted stock units that vest in four equal annual installments beginning on February 24, 2024. Read SEC document |
| February 23, 2023 Filed Feb 28, 2023 01:10 UTC | Avantor, Inc. AVTR · Entity 3546 | Tax withholdingCommon Stock | 1,893 | $24.59 | $46,548.87 |
DisclosureSEC source: 0001722482-23-000075 · wf-form4_167754659342287.xml · nonDerivative · entry 1 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,420 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| February 20, 2023 Filed Feb 22, 2023 21:58 UTC | Avantor, Inc. AVTR · Entity 3546 | Tax withholdingCommon Stock | 3,072 | $24.54 | $75,386.88 |
DisclosureSEC source: 0001722482-23-000059 · wf-form4_167710309252848.xml · nonDerivative · entry 1 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,313 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 01:25 UTC | Avantor, Inc. AVTR · Entity 3546 | SaleCommon Stock | 11,339 | $25.06 | $284,155.34 |
DisclosureSEC source: 0001722482-23-000023 · wf-form4_167538752663268.xml · nonDerivative · entry 3 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,385 F3 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $25.00 to $25.15, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth above. Read SEC document |
| January 31, 2023 Filed Feb 3, 2023 01:25 UTC | Avantor, Inc. AVTR · Entity 3546 | Tax withholdingCommon Stock | 15,221 | $23.90 | $363,781.90 |
DisclosureSEC source: 0001722482-23-000023 · wf-form4_167538752663268.xml · nonDerivative · entry 2 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,724 F2 · kind: Reflects shares of Common Stock withheld to cover the Reporting Person's tax liability in connection with the vesting and settlement of the performance-based restricted stock units described herein. Read SEC document |
| January 31, 2023 Filed Feb 3, 2023 01:25 UTC | Avantor, Inc. AVTR · Entity 3546 | GrantCommon Stock | 38,737 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-23-000023 · wf-form4_167538752663268.xml · nonDerivative · entry 1 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,945 F1 · kind: Reflects performance-based restricted stock units previously granted to the Reporting Person, the performance of which was certified on January 31, 2023. Each performance-based restricted stock unit represents a contingent right to receive one share of Common Stock of the Issuer. Read SEC document |
| January 02, 2023 Filed Jan 4, 2023 21:58 UTC | Avantor, Inc. AVTR · Entity 3546 | Tax withholdingCommon Stock | 6,727 | $21.09 | $141,872.43 |
DisclosureSEC source: 0001722482-23-000008 · wf-form4_167286946695888.xml · nonDerivative · entry 1 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,208 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| May 20, 2022 Filed May 23, 2022 20:46 UTC | Avantor, Inc. AVTR · Entity 3546 | SaleCommon Stock | 19,603 | $31.27 | $612,985.81 |
DisclosureSEC source: 0001722482-22-000147 · wf-form4_165333876779150.xml · nonDerivative · entry 1 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,935 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $31.14 to $31.39, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth above. Read SEC document |
| May 17, 2022 Filed May 19, 2022 20:13 UTC | Avantor, Inc. AVTR · Entity 3546 | Tax withholdingCommon Stock | 19,683 | $31.33 | $616,668.39 |
DisclosureSEC source: 0001722482-22-000139 · wf-form4_165299118031958.xml · nonDerivative · entry 1 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,538 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 22:07 UTC | Avantor, Inc. AVTR · Entity 3546 | SaleCommon Stock | 2,027 | $34.47 | $69,870.69 |
DisclosureSEC source: 0001722482-22-000067 · wf-form4_164625880570239.xml · nonDerivative · entry 1 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,221 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| February 25, 2022 Filed Feb 26, 2022 02:32 UTC | Avantor, Inc. AVTR · Entity 3546 | Tax withholdingCommon Stock | 2,043 | $35.39 | $72,301.77 |
DisclosureSEC source: 0001722482-22-000061 · wf-form4_164584265312525.xml · nonDerivative · entry 3 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,248 F4 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSU's. Read SEC document |
| February 23, 2022 Filed Feb 26, 2022 02:32 UTC | Avantor, Inc. AVTR · Entity 3546 | GrantStock Options (Right to Buy) · Derivative | 43,708 | $0.00 Strike: $33.09 | $0.00 |
DisclosureSEC source: 0001722482-22-000061 · wf-form4_164584265312525.xml · derivative · entry 4 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,708 Underlying: Common Stock · 43,708 shares Expires 2032-02-23 F5 · derivative.exercise_date: Reflects a grant of stock options that vest in four equal annual installments beginning on February 23, 2023. Read SEC document |
| February 23, 2022 Filed Feb 26, 2022 02:32 UTC | Avantor, Inc. AVTR · Entity 3546 | GrantCommon Stock | 15,110 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-22-000061 · wf-form4_164584265312525.xml · nonDerivative · entry 2 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,291 F3 · kind: Reflects a grant of restricted stock units that vest in four equal annual installments beginning on February 23, 2023. Read SEC document |
| February 23, 2022 Filed Feb 26, 2022 02:32 UTC | Avantor, Inc. AVTR · Entity 3546 | SaleCommon Stock | 3,059 | $33.79 | $103,363.61 |
DisclosureSEC source: 0001722482-22-000061 · wf-form4_164584265312525.xml · nonDerivative · entry 1 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,181 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $33.75 to $33.94 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth above. Read SEC document |
| February 20, 2022 Filed Feb 22, 2022 22:27 UTC | Avantor, Inc. AVTR · Entity 3546 | Tax withholdingCommon Stock | 3,072 | $34.00 | $104,448.00 |
DisclosureSEC source: 0001722482-22-000044 · wf-form4_164556883314906.xml · nonDerivative · entry 1 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,240 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| January 05, 2022 Filed Jan 5, 2022 21:59 UTC | Avantor, Inc. AVTR · Entity 3546 | SaleCommon Stock | 11,551 | $38.65 | $446,446.15 |
DisclosureSEC source: 0001722482-22-000011 · wf-form4_164141993911167.xml · nonDerivative · entry 4 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,312 F2 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $38.44 to $38.87, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth above. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:59 UTC | Avantor, Inc. AVTR · Entity 3546 | Exercise / conversionStock Options (Right to Buy) · Derivative | 59,418 | $0.00 Strike: $18.45 | $0.00 |
DisclosureSEC source: 0001722482-22-000011 · wf-form4_164141993911167.xml · derivative · entry 5 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,417 Underlying: Common Stock · 59,418 shares Expires 2030-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Reflects an initial grant of 178,253 stock options that vest in three equal installments beginning on January 2, 2021. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:59 UTC | Avantor, Inc. AVTR · Entity 3546 | SaleCommon Stock | 59,418 | $40.77 | $2,422,471.86 |
DisclosureSEC source: 0001722482-22-000011 · wf-form4_164141993911167.xml · nonDerivative · entry 3 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,863 F2 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $40.27 to $41.97, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth above. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:59 UTC | Avantor, Inc. AVTR · Entity 3546 | Exercise / conversionCommon Stock | 59,418 | $18.45 | $1,096,262.10 |
DisclosureSEC source: 0001722482-22-000011 · wf-form4_164141993911167.xml · nonDerivative · entry 2 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,281 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2022 Filed Jan 5, 2022 21:59 UTC | Avantor, Inc. AVTR · Entity 3546 | Tax withholdingCommon Stock | 6,516 | $42.14 | $274,584.24 |
DisclosureSEC source: 0001722482-22-000011 · wf-form4_164141993911167.xml · nonDerivative · entry 1 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,863 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| July 30, 2021 Filed Aug 2, 2021 20:42 UTC | Avantor, Inc. AVTR · Entity 3546 | Exercise / conversionStock Options (Right to Buy) · Derivative | 81,125 | $0.00 Strike: $23.21 | $0.00 |
DisclosureSEC source: 0001722482-21-000214 · wf-form4_162793693617476.xml · derivative · entry 3 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,125 Underlying: Common Stock · 81,125 shares Expires 2028-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Reflects an initial grant of 540,830 stock options in which 40% vested at the time of IPO and the remaining 60% that vests in four equal installments beginning on July 30, 2019. Read SEC document |
| July 30, 2021 Filed Aug 2, 2021 20:42 UTC | Avantor, Inc. AVTR · Entity 3546 | SaleCommon Stock | 81,125 | $37.24 | $3,021,095.00 |
DisclosureSEC source: 0001722482-21-000214 · wf-form4_162793693617476.xml · nonDerivative · entry 2 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,379 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $36.65 to $37.51, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth above. Read SEC document |
| July 30, 2021 Filed Aug 2, 2021 20:42 UTC | Avantor, Inc. AVTR · Entity 3546 | Exercise / conversionCommon Stock | 81,125 | $23.20 | $1,882,100.00 |
DisclosureSEC source: 0001722482-21-000214 · wf-form4_162793693617476.xml · nonDerivative · entry 1 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 20, 2021 Filed May 21, 2021 20:54 UTC | Avantor, Inc. AVTR · Entity 3546 | SaleCommon Stock | 19,603 | $31.10 | $609,653.30 |
DisclosureSEC source: 0001722482-21-000160 · wf-form4_162163047642844.xml · nonDerivative · entry 1 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,379 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $30.96 to $31.24, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth above. Read SEC document |
| May 17, 2021 Filed May 19, 2021 21:17 UTC | Avantor, Inc. AVTR · Entity 3546 | Tax withholdingCommon Stock | 19,683 | $30.90 | $608,204.70 |
DisclosureSEC source: 0001722482-21-000154 · wf-form4_162145902468877.xml · nonDerivative · entry 1 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,982 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 22:25 UTC | Avantor, Inc. AVTR · Entity 3546 | GrantStock Options (Right to Buy) · Derivative | 52,693 | $0.00 Strike: $27.64 | $0.00 |
DisclosureSEC source: 0001722482-21-000080 · wf-form4_161463743593570.xml · derivative · entry 2 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,693 Underlying: Common Stock · 52,693 shares Expires 2031-02-25 F2 · derivative.exercise_date: Reflects a grant of stock options that vest in four equal annual installments beginning on February 25, 2022. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 22:25 UTC | Avantor, Inc. AVTR · Entity 3546 | GrantCommon Stock | 16,281 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-21-000080 · wf-form4_161463743593570.xml · nonDerivative · entry 1 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,665 F1 · kind: Reflects a grant of restricted stock units that vest in four equal annual installments beginning on February 25, 2022. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 23:34 UTC | Avantor, Inc. AVTR · Entity 3546 | SaleCommon Stock | 3,059 | $27.93 | $85,437.87 |
DisclosureSEC source: 0001722482-21-000057 · wf-form4_161438242739247.xml · nonDerivative · entry 1 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,384 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 22:51 UTC | Avantor, Inc. AVTR · Entity 3546 | Exercise / conversionStock Options (Right to Buy) · Derivative | 19,769 | $0.00 Strike: $17.67 | $0.00 |
DisclosureSEC source: 0001722482-21-000054 · wf-form4_161412066010117.xml · derivative · entry 4 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,306 Underlying: Common Stock · 19,769 shares Expires 2030-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Reflects an initial grant of 79,075 stock options that vest in four equal installments beginning on February 21, 2021. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 22:51 UTC | Avantor, Inc. AVTR · Entity 3546 | SaleCommon Stock | 19,769 | $28.62 | $565,788.78 |
DisclosureSEC source: 0001722482-21-000054 · wf-form4_161412066010117.xml · nonDerivative · entry 3 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,443 F2 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $28.54 to $28.67, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth above. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 22:51 UTC | Avantor, Inc. AVTR · Entity 3546 | Exercise / conversionCommon Stock | 19,769 | $17.67 | $349,318.23 |
DisclosureSEC source: 0001722482-21-000054 · wf-form4_161412066010117.xml · nonDerivative · entry 2 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,212 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 22:51 UTC | Avantor, Inc. AVTR · Entity 3546 | Tax withholdingCommon Stock | 3,072 | $28.69 | $88,135.68 |
DisclosureSEC source: 0001722482-21-000054 · wf-form4_161412066010117.xml · nonDerivative · entry 1 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,443 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 22:41 UTC | Avantor, Inc. AVTR · Entity 3546 | Exercise / conversionStock Options (Right to Buy) · Derivative | 162,248 | $0.00 Strike: $23.21 | $0.00 |
DisclosureSEC source: 0001722482-21-000025 · wf-form4_161057768826138.xml · derivative · entry 5 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,250 Underlying: Common Stock · 162,248 shares Expires 2028-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Reflects an initial grant of 540,830 stock options in which 40% vested at the time of IPO and the remaining 60% that vests in four equal installments beginning on July 30, 2019. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 22:41 UTC | Avantor, Inc. AVTR · Entity 3546 | SaleCommon Stock | 162,248 | $30.04 | $4,873,929.92 |
DisclosureSEC source: 0001722482-21-000025 · wf-form4_161057768826138.xml · nonDerivative · entry 4 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,515 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $30.00 to $30.21, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth above Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 22:41 UTC | Avantor, Inc. AVTR · Entity 3546 | Exercise / conversionCommon Stock | 162,248 | $23.20 | $3,764,153.60 |
DisclosureSEC source: 0001722482-21-000025 · wf-form4_161057768826138.xml · nonDerivative · entry 3 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,763 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 22:41 UTC | Avantor, Inc. AVTR · Entity 3546 | SaleCommon Stock | 216,332 | $30.08 | $6,507,266.56 |
DisclosureSEC source: 0001722482-21-000025 · wf-form4_161057768826138.xml · nonDerivative · entry 2 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,515 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $30.00 to $30.33, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth above. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 22:41 UTC | Avantor, Inc. AVTR · Entity 3546 | Exercise / conversionCommon Stock | 216,332 | $23.20 | $5,018,902.40 |
DisclosureSEC source: 0001722482-21-000025 · wf-form4_161057768826138.xml · nonDerivative · entry 1 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 394,847 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2021 Filed Jan 9, 2021 00:31 UTC | Avantor, Inc. AVTR · Entity 3546 | SaleCommon Stock | 11,509 | $27.24 | $313,505.16 |
DisclosureSEC source: 0001722482-21-000021 · wf-form4_161015226274868.xml · nonDerivative · entry 1 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,515 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $27.07 to $27.54, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth above. Read SEC document |
| January 04, 2021 Filed Jan 7, 2021 02:06 UTC | Avantor, Inc. AVTR · Entity 3546 | Exercise / conversionStock Options (Right to Buy) · Derivative | 59,418 | $0.00 Strike: $18.45 | $0.00 |
DisclosureSEC source: 0001722482-21-000010 · wf-form4_160998518340532.xml · derivative · entry 4 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,835 Underlying: Common Stock · 59,418 shares Expires 2030-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Reflects an initial grant of 178,253 stock options that vest in three equal installments beginning on January 2, 2021. Read SEC document |
| January 04, 2021 Filed Jan 7, 2021 02:06 UTC | Avantor, Inc. AVTR · Entity 3546 | SaleCommon Stock | 59,418 | $27.84 | $1,654,197.12 |
DisclosureSEC source: 0001722482-21-000010 · wf-form4_160998518340532.xml · nonDerivative · entry 3 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,024 F2 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $27.63 to $28.31, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth above. Read SEC document |
| January 04, 2021 Filed Jan 7, 2021 02:06 UTC | Avantor, Inc. AVTR · Entity 3546 | Exercise / conversionCommon Stock | 59,418 | $18.45 | $1,096,262.10 |
DisclosureSEC source: 0001722482-21-000010 · wf-form4_160998518340532.xml · nonDerivative · entry 2 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,442 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2021 Filed Jan 7, 2021 02:06 UTC | Avantor, Inc. AVTR · Entity 3546 | Tax withholdingCommon Stock | 6,559 | $28.15 | $184,635.85 |
DisclosureSEC source: 0001722482-21-000010 · wf-form4_160998518340532.xml · nonDerivative · entry 1 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,024 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| May 20, 2020 Filed May 22, 2020 20:22 UTC | Avantor, Inc. AVTR · Entity 3546 | SaleCommon Stock | 25,495 | $17.36 | $442,593.20 |
DisclosureSEC source: 0001722482-20-000126 · wf-form4_159017891888678.xml · nonDerivative · entry 1 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,583 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $17.10 to $17.60, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth above. Read SEC document |
| May 17, 2020 Filed May 19, 2020 22:55 UTC | Avantor, Inc. AVTR · Entity 3546 | Tax withholdingCommon Stock | 13,790 | $17.86 | $246,289.40 |
DisclosureSEC source: 0001722482-20-000120 · wf-form4_158992891331047.xml · nonDerivative · entry 1 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,078 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:21 UTC | Avantor, Inc. AVTR · Entity 3546 | GrantStock Options (Right to Buy) · Derivative | 79,075 | $0.00 Strike: $17.67 | $0.00 |
DisclosureSEC source: 0001722482-20-000049 · wf-form4_158266928020210.xml · derivative · entry 2 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,075 Underlying: Common Stock · 79,075 shares Expires 2030-02-21 F2 · derivative.exercise_date: Reflects a grant of stock options that vest in four equal annual installments beginning on February 21, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.